Interventional Pulmonology solutions company Pulmonx®, has acquired the assets of Aeris Therapeutics, maker of AeriSeal®, a foam-based lung sealant system for the treatment of emphysema, a form of chronic obstructive pulmonary disease (COPD).
Just before Christmas we were telling you that Pulmonx had gained a new CEO. Now the company is adding to its product portfolio with the acquisition of a technology that it expects will significantly expand the treatable patient population for the company’s therapies.
The AeriSeal treatment uses a foam sealant to block diseased regions in the lung to achieve volume reduction and improve breathing function. The treatment is independent of collateral ventilation and is designed for patients with heterogeneous and homogeneous emphysema, thereby enlarging the patient pool for Pulmonx’ therapies. AeriSeal is delivered in a simple procedure that does not require evaluation of available lung tissue or tissue integrity. AeriSeal is expected to be commercially available in Europe upon reissuance of the CE Mark, which is expected in the second half of 2015.
“Our Zephyr EBV device has been proven to significantly and predictably improve symptoms in certain advanced emphysema patients. By adding AeriSeal to our portfolio, we will be filling a treatment gap, enabling us to treat almost the entire spectrum of advanced emphysema patients,” said Pulmonx Chief Executive Officer Glen French. “We will be performing additional development work on AeriSeal to enhance its clinical profile and are confident that we will be able to deliver an effective treatment to physicians.”